Order Toll Free: 1-888-848-1945. You save an additional 20% by ordering online.

Welcome! Log in:

Forgot password?
Do I need an account to order?
River Professional Group - Your Neighborhood Drugstore Online

Frequently Asked Questions

What can you tell me about Low Dose Naltrexone (LDN)?

Short Answer

It is an alternative (off-label) use of Naltrexone (also known as Revia or Nodict) for such conditions as Multiple Sclerosis (MS), certain types of cancer, Crohn's Disease, and others.

Long Answer

Naltrexone is an oral medication that is approved in several countries for the treatment of opiate addiction. In 2006, the U.S. Food and Drug Administration (FDA) approved Naltrexone extended-release injection for once-monthly administration by a health care professional in the treatment of alcohol addiction. Any off-label use of the medication has not been formally approved by the FDA and other similar organizations as of early 2007.

Having said that, many medical professionals have been using Naltrexone with their patients for other conditions for many years. You should talk to your health care professional before using this or any medication.

One method for taking low dose Naltrexone is to take a 50 mg Naltrexone tablet and dissolve it in 50 ml of distilled water. Then it can be dosed with a measured dropper or syringe (no needle) to the 3 mg to 5 mg dosage that is commonly required. The remaining solution is usually refrigerated for storage.

Additional Information

Multiple Sclerosis

Low Dose Naltrexone: Modern Miracle Drug
Naltrexone is an inexpensive generic pharmaceutical approved by the United States Food and Drug Administration for treating opiate and alcohol addiction. In very low doses, it is being found a cost-effective means of treating a wide range of health concerns, including HIV/AIDS, certain types of cancer, and a number of autoimmune and neurodegenerative disorders. Side effects are usually both mild and transitory.

One small nightly dose of Naltrexone has the effect of temporarily blocking certain opioid receptors.
"Save our Sick, Save our Economy"
"Low Dose Naltrexone (LDN) is a drug that is credited with helping those with HIV/AIDS, cancer, autoimmune diseases, and central nervous system disorders (including MS) by boosting (modulating) the immune system. As well as being effective it is cheap, costing less than one pound a day, and could save the NHS vast sums of money. We therefore urge the Government to fund a trial of LDN on the NHS so that everyone in the UK can reap the benefits of this drug."

Stephen Crabb MP
Low Dose Naltrexone in the treatment of Multiple Sclerosis
LDN is a treatment method that has been in use in the USA since 1985 but is relatively new in this country. Despite its claimed successful use in America, until fully proved in the UK, it must be considered as experimental and that no beneficial response can be guaranteed. In addition, despite the fact that the drug is at a very low dose, the absence of significant introductory or prolonged side-effects cannot be excluded.
This is MS Responds to NMSS Article on LDN
The (US) National Multiple Sclerosis Society has just published an article advising against the use of Low Dose Naltrexone (LDN) for MS (May 2004).

Crohn's Disease

American Journal of Gastroenterology
In the January issue (2007;102:1�9), Dr. Jill Smith (et al) of the Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA writes an article called Low-Dose Naltrexone Therapy Improves Active Crohn's Disease.
Crohn's disease is a type of inflammatory bowel disease (IBD) and can affect any part of the gastrointestinal tract from mouth to anus; as a result, the symptoms of Crohn's disease can vary between affected individuals. The main gastrointestinal symptoms are abdominal pain, diarrhea, which may be bloody, and weight loss.


Intravenous Alpha-Lipoic Acid/Low-Dose Naltrexone Protocol
The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous alpha-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program. The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy.


Low Dose Naltrexone in the Treatment of HIV Infection
Dr. Bernard Bihari of New York City used low doseages of naltrexone to stimulate immune function in AIDS patients in 1985. [More] [More] [More] [More] [More]


Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)
This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language. (Last Updated: May 2, 2006)